rs185972191
Positions:
Variant summary
Our verdict is Benign. Variant got -13 ACMG points: 0P and 13B. BP4_StrongBP6BS1BS2
The ENST00000648064.1(ALDOB):​c.-10-5015G>A variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00679 in 152,140 control chromosomes in the GnomAD database, including 5 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Genomes: đť‘“ 0.0068 ( 5 hom., cov: 32)
Exomes đť‘“: 0.0 ( 0 hom. )
Failed GnomAD Quality Control
Consequence
ALDOB
ENST00000648064.1 intron
ENST00000648064.1 intron
Scores
2
Clinical Significance
Conservation
PhyloP100: 0.904
Genes affected
ALDOB (HGNC:417): (aldolase, fructose-bisphosphate B) Fructose-1,6-bisphosphate aldolase (EC 4.1.2.13) is a tetrameric glycolytic enzyme that catalyzes the reversible conversion of fructose-1,6-bisphosphate to glyceraldehyde 3-phosphate and dihydroxyacetone phosphate. Vertebrates have 3 aldolase isozymes which are distinguished by their electrophoretic and catalytic properties. Differences indicate that aldolases A, B, and C are distinct proteins, the products of a family of related 'housekeeping' genes exhibiting developmentally regulated expression of the different isozymes. The developing embryo produces aldolase A, which is produced in even greater amounts in adult muscle where it can be as much as 5% of total cellular protein. In adult liver, kidney and intestine, aldolase A expression is repressed and aldolase B is produced. In brain and other nervous tissue, aldolase A and C are expressed about equally. There is a high degree of homology between aldolase A and C. Defects in ALDOB cause hereditary fructose intolerance. [provided by RefSeq, Dec 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -13 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.7).
BP6
Variant 9-101435912-C-T is Benign according to our data. Variant chr9-101435912-C-T is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 500745.We mark this variant Likely_benign, oryginal submissions are: {Benign=2, Uncertain_significance=3}.
BS1
Variant frequency is greater than expected in population amr. gnomad4 allele frequency = 0.00679 (1033/152140) while in subpopulation AMR AF= 0.00949 (145/15284). AF 95% confidence interval is 0.00881. There are 5 homozygotes in gnomad4. There are 463 alleles in male gnomad4 subpopulation. Median coverage is 32. This position pass quality control queck.
BS2
High Homozygotes in GnomAd4 at 5 AR gene
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
ALDOB | ENST00000648064.1 | c.-10-5015G>A | intron_variant | ENSP00000497990 | P1 | |||||
ALDOB | ENST00000648423.1 | c.-64-150G>A | intron_variant | ENSP00000497985 | ||||||
ALDOB | ENST00000648758.1 | c.-10-5015G>A | intron_variant | ENSP00000497731 | P1 |
Frequencies
GnomAD3 genomes AF: 0.00680 AC: 1034AN: 152022Hom.: 5 Cov.: 32
GnomAD3 genomes
AF:
AC:
1034
AN:
152022
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD4 exome Data not reliable, filtered out with message: AC0 AF: 0.00 AC: 0AN: 10Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 10
GnomAD4 exome
Data not reliable, filtered out with message: AC0
AF:
AC:
0
AN:
10
Hom.:
AF XY:
AC XY:
0
AN XY:
10
Gnomad4 AFR exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 NFE exome
AF:
GnomAD4 genome AF: 0.00679 AC: 1033AN: 152140Hom.: 5 Cov.: 32 AF XY: 0.00622 AC XY: 463AN XY: 74398
GnomAD4 genome
AF:
AC:
1033
AN:
152140
Hom.:
Cov.:
32
AF XY:
AC XY:
463
AN XY:
74398
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
2
AN:
3478
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Pathogenic:1Uncertain:3Benign:2
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
not provided Uncertain:3Benign:1
Benign, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Sep 01, 2023 | ALDOB: BS1, BS2 - |
Uncertain significance, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | May 22, 2018 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Jul 07, 2022 | BS1 - |
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Mar 04, 2020 | Functional studies found that this variant causes loss of transcription from the promoter (Coffee et al., 2010); Nucleotide substitution has no predicted effect on splicing and is not conserved across species; This variant is associated with the following publications: (PMID: 20882353, 25910213) - |
Hereditary fructosuria Pathogenic:1Benign:1
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 13, 2023 | - - |
Pathogenic, no assertion criteria provided | literature only | ATS em GenĂ©tica ClĂnica, Universidade Federal do Rio Grande do Sul | Mar 18, 2021 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at